Sanggenol L Induces Ferroptosis in NSCLC: Mechanistic Insights via miR-26a-1-3p/MDM2/p53 Regulation

Study Background and Research Question

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and continues to be a leading cause of cancer mortality worldwide, with an estimated 1.8 million deaths in 2020. While platinum-based chemotherapies remain a mainstay for advanced NSCLC, resistance and adverse effects limit their long-term effectiveness. Recent interest in ferroptosis—a regulated, iron-dependent form of cell death driven by lipid peroxidation—stems from its potential to overcome resistance in tumors that evade apoptosis. Natural products, especially those with a history of medicinal use, are increasingly explored as sources of novel anti-cancer agents. The reference study focuses on sanggenol L, a bioactive compound from mulberry (Morus alba L.) bark, and investigates whether it can selectively induce ferroptosis in NSCLC cells and by what molecular pathways (reference study).

Key Innovation from the Reference Study

The central innovation lies in uncovering a mechanistic link between sanggenol L and the induction of ferroptosis in NSCLC cells via the miR-26a-1-3p/MDM2/p53/SLC7A11 axis. Unlike prior research that focused mainly on the apoptotic effects of sanggenol L, this study demonstrates its ability to upregulate miR-26a-1-3p, which directly targets the E3 ubiquitin ligase MDM2. The resulting suppression of MDM2 elevates p53 protein levels, leading to downregulation of SLC7A11—a key component in glutathione synthesis and cellular redox balance. This cascade ultimately increases cellular susceptibility to ferroptotic death, providing a novel route for therapeutic intervention in chemoresistant NSCLC (reference study).

Methods and Experimental Design Insights

The study employed a multifaceted approach combining in vitro and in vivo analyses. NSCLC cell lines were treated with sanggenol L, followed by assessments of cell viability, proliferation, and markers of ferroptosis including reactive oxygen species (ROS) accumulation, glutathione (GSH) depletion, mitochondrial morphology, and lipid peroxidation. The use of ferroptosis inhibitors (e.g., ferrostatin-1) helped confirm specificity. A ferroptosis-related miRNA array identified miR-26a-1-3p as a key upregulated transcript post-treatment. Luciferase reporter assays and gene silencing experiments further validated the direct interaction between miR-26a-1-3p and MDM2. For translational relevance, the efficacy and safety of sanggenol L were tested in both subcutaneous xenograft and patient-derived xenograft (PDX) mouse models.

Protocol Parameters

• Sanggenol L treatment: Expose NSCLC cell lines to sanggenol L at concentrations ranging from 5–40 μM for 24–48 hours to assess dose- and time-dependent effects on cell death and ferroptosis markers.
• Cell proliferation assays: Incorporate 5-ethynyl-2'-deoxyuridine (EdU) or equivalent S-phase tracers during the final 2 hours of treatment to quantify proliferation changes.
• Ferroptosis confirmation: Co-treat with ferroptosis inhibitors (e.g., 1–2 μM ferrostatin-1) and compare to apoptosis or necroptosis inhibitors as controls.
• miRNA interference: Transfect cells with miR-26a-1-3p mimics/inhibitors or MDM2-targeting siRNAs 24 hours prior to sanggenol L exposure to dissect pathway dependency.
• In vivo dosing: Administer sanggenol L at 20–40 mg/kg by intraperitoneal injection in xenograft models, monitoring tumor size and animal health over 4–6 weeks.

Core Findings and Why They Matter

Sanggenol L induced hallmark features of ferroptosis in NSCLC cells, including significant ROS accumulation, GSH depletion, mitochondrial shrinkage, and increased lipid peroxidation. Upregulation of miR-26a-1-3p was pivotal, as it directly suppressed MDM2, a negative regulator of the tumor suppressor p53. Elevated p53 in turn reduced SLC7A11 levels, sensitizing cells to ferroptosis by limiting cystine uptake and glutathione synthesis. Inhibition of MDM2 or overexpression of miR-26a-1-3p potentiated these effects, while intervention at any step of the axis (e.g., p53 knockdown, ferroptosis inhibition) reversed them. In vivo, sanggenol L suppressed tumor growth in both subcutaneous and PDX models, with minimal toxicity, supporting translational potential (reference study).

These results suggest that the miR-26a-1-3p/MDM2/p53/SLC7A11 signaling cascade is a critical mediator of ferroptosis in NSCLC and may be exploited to overcome chemoresistance where apoptosis-based therapies fail.

Comparison with Existing Internal Articles

Recent internal articles highlight the value of advanced cell proliferation and S-phase DNA synthesis assays in oncology research. For example, one comparative review discusses how EdU Imaging Kits (Cy3) facilitate robust, denaturation-free detection of DNA synthesis, offering advantages for genotoxicity testing and cell cycle analysis in cancer models. Another article details the role of click chemistry-based EdU assays in dissecting drug effects in the tumor microenvironment, a context highly relevant to the present study's focus on ferroptosis-inducing agents. Integrating cell proliferation readouts with ferroptosis markers—enabled by these EdU-based methods—offers a more complete picture of how agents like sanggenol L impact both cell viability and cell cycle progression.

Limitations and Transferability

While the study demonstrates compelling preclinical efficacy, several limitations merit consideration. First, the in vitro findings were validated in xenograft models but not in immunocompetent systems, which may influence tumor-immune interactions. Second, while the miR-26a-1-3p/MDM2/p53/SLC7A11 axis is clearly implicated, other regulatory pathways could modulate ferroptosis sensitivity. The specificity of sanggenol L for cancer versus normal cells also requires further investigation before clinical translation. Finally, the use of established cell lines and PDX models, though informative, does not fully recapitulate the heterogeneity of patient tumors.

Despite these caveats, the mechanistic insights are highly transferable to broader research on ferroptosis and drug resistance in cancer. Researchers investigating alternative cell death modalities, genotoxicity, or cell cycle S-phase DNA synthesis measurement can directly leverage the molecular signatures and workflow outlined here.

Research Support Resources

To facilitate similar investigations into cell proliferation and ferroptosis in cancer models, researchers may employ EdU Imaging Kits (Cy3) (SKU K1075) from APExBIO. These kits offer sensitive, denaturation-free detection of DNA synthesis via copper-catalyzed azide-alkyne cycloaddition (CuAAC), enabling high-content fluorescence microscopy cell proliferation assays alongside ferroptosis marker analysis. For additional workflow guidance and comparative insights, see the detailed reviews linked above. EdU-based approaches have proven especially valuable for integrating S-phase quantification within multi-parametric cancer research workflows.